glp-1 latest news drugs promise wider health benefits, but experts urge caution on use GLP-1 Pipeline Update: August 2025

I dont read social media, but Im told there is a lot of support there as well

doi: 10.1038/s41588-021-00913-z

Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023)

Patients with diabetes and retinopathy should be monitored closely, as rapid improvement in glucose control may be associated with temporary worsening of retinopathy

The most frequently reported issues include: Nausea : 21.49% of patients Diarrhea : 10.62% Vomiting : 9.10% Dyspepsia (indigestion) : 8.67% Constipation : 7.92% Decreased appetite : 5.49% While many tolerate these medications well, over 10% of patients stop or interrupt treatment due to severe discomfort

Insurance covers GLP-1 medications for conditions such as diabetes or heart disease far more reliably than for weight loss